Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AssigneeG.D. Searle & Co.
InventorsJohn J Talley, John R Medich, Kathleen T McLaughlin, Henry T Gaud, Edward E Yonan
Life of this patent
Estimating the term…
Abstract
A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.
Claims13
A crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide having a melting point of about 170-174° C.
A pharmaceutical composition comprising a therapeutically-effective amount of crystalline Form B of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.
A method of treating a cyclooxygenase-2 associated disorder in a subject, said method comprising treating the subject having or susceptible to said disorder with a therapeutically-effective amount of the crystalline Form B of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide.
Dependencies are inferred from the claim text.